- Pharma
- 1 min read
DFE Pharma’s CoE in Genome Valley
The new centre will mainly focus on oral solid dosage (OSD) forms and offer a range of pre-registration work including development, scale-up, and technology transfer
The C2F CoE, which includes 1,200-sq mt laboratory facilities, will help global and local pharmaceutical and nutraceutical companies shorten the time from concept to finished commercial products by developing formulations that allow for scale-up, high-speed production, and first-to-market launch, the company said.
The new center will mainly focus on oral solid dosage (OSD) forms and offer a range of pre-registration work including development, scale-up, and technology transfer.
“The capabilities also include efficiency projects like conversions from wet granulation to direct compression.
The center will work with active pharmaceutical ingredients (APIs), including innovative concepts as model APIs, and with a broad portfolio of all categories of excipients and their different grades,” it added.
Inaugurating the C2F centre, Telangana industries minister KT Rama Rao, said, the C2F will further strengthen the potential for growth and support offered by Genome Valley.
“The government of Telangana will work with DFE Pharma to ensure that life sciences companies in the state leverage this facility,” he said.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions